As detailed in a recent systematic review and meta–analysis by Xia and colleagues, autoantibodies against p53, MUC1, HER2, and cyclin B1 are the top 4 among all breast cancer-associated autoantibodies in terms of the frequency of studies. This evidence concerns the gene ERBB2 and breast carcinoma.